← Back to Clinical Trials
Recruiting NCT06296550

NCT06296550 Enhancing Digitally Delivered Diabetes Education With Real-Time CGM

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06296550
Status Recruiting
Phase
Sponsor Scripps Whittier Diabetes Institute
Condition Diabetes Type 2
Study Type INTERVENTIONAL
Enrollment 140 participants
Start Date 2025-04-03
Primary Completion 2027-04-30

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Dulce Digital Text Messaging InterventionCGM Device

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 140 participants in total. It began in 2025-04-03 with a primary completion date of 2027-04-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The current research study will add continuous glucose monitoring devices to the evidence-based text messaging diabetes education program for patients with type 2 diabetes for 6 months. Results on the effectiveness of this intervention will be compared for non-insulin using patients.

Eligibility Criteria

Inclusion Criteria: * Diagnosed with type 2 diabetes * Are not currently using a CGM * Are not using insulin therapies * Speak English, Spanish or Arabic * Have A1c between 7.5% and 12.0% in last 90 days * Have a cellphone that can receive/send text messages and counts steps Exclusion Criteria: * Are using insulin therapies * Are pregnant * Are currently using a CGM * Are currently participating in another diabetes-related study

Contact & Investigator

Central Contact

Kallie Brown, PhD

✉ brown.kallie@scrippshealth.org

📞 858-258-3555

Principal Investigator

Athena Philis-Tsimikas, MD

PRINCIPAL INVESTIGATOR

Scripps Health

Frequently Asked Questions

Who can join the NCT06296550 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Diabetes Type 2. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06296550 currently recruiting?

Yes, NCT06296550 is actively recruiting participants. Contact the research team at brown.kallie@scrippshealth.org for enrollment information.

Where is the NCT06296550 trial being conducted?

This trial is being conducted at San Diego, United States.

Who is sponsoring the NCT06296550 clinical trial?

NCT06296550 is sponsored by Scripps Whittier Diabetes Institute. The principal investigator is Athena Philis-Tsimikas, MD at Scripps Health. The trial plans to enroll 140 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology